ACOBIOM develops innovative medical Diagnostics in order to select the best-in-class treatment that matches the patient’s own biological profile. The company is currently involved in the development of several Tests in Oncology and Neurology.
These Diagnostics are non invasive and can be performed from a blood sample. They have been developing for routine uses on platforms already used in central labs and clinical centres.
ACOBIOM’s Diagnostics (cf pipeline below) are the results of the combination of a 18-year technical know-how in genomics, of Bioinformatics tools dedicated to genomics data analysis, of a proprietary database containg 27,000 genomics profiles (BIG DATA), and of a unique scientific expertise in the analysis of genomics data from blood cells and total blood.
ACOBIOM’s business positions the company in several growing markets that generate important revenues as:
> Biomarkers : USD 53.34 Billion by 2021 from USD 27.95 Billion in 2016, growing at a CAGR of 13.8% during the forecast period (2016-2021) (source : Markets & Markets).
> Companion Diagnostics: USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, growing at a CAGR of 20.1% during the forecast period (2017-2022) (source: Markets & Markets).
Financial partners, interested in sharing the ambitions and the objective of ACOBIOM to commercialize innovative medical Diagnostics to improve treatments on oncology and neurology, can contact the company to read the Executive Summary and the documents dedicated to investors.
To obtain more information about ACOBIOM, its Diagnostic pipeline, and about the seeking funds in 2017 & 2018, please contact Philippe Outrebon (email@example.com, T: +33(0)467 419 748).